145 related articles for article (PubMed ID: 34174766)
1. Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study.
Mamguem Kamga A; Billa O; Ladoire S; Poillot ML; Jolimoy G; Roignot P; Coutant C; Desmoulins I; Maynadie M; Dabakuyo-Yonli TS
Breast; 2021 Oct; 59():79-86. PubMed ID: 34174766
[TBL] [Abstract][Full Text] [Related]
2. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
4. OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database.
Hu K; He P; Peng Q; Zhong X; Deng L; Xie Y; Li J; Xu H; Lu D; Zheng H
Breast Cancer; 2019 May; 26(3):339-348. PubMed ID: 30367358
[TBL] [Abstract][Full Text] [Related]
5. Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women.
Nayyar A; Strassle PD; Iles K; Jameison D; Jadi J; McGuire KP; Gallagher KK
Ann Surg Oncol; 2020 Nov; 27(12):4853-4860. PubMed ID: 32918178
[TBL] [Abstract][Full Text] [Related]
6. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
[TBL] [Abstract][Full Text] [Related]
7. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
8. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
Jacob L; Hadji P; Kostev K
J Geriatr Oncol; 2016 May; 7(3):169-75. PubMed ID: 27091510
[TBL] [Abstract][Full Text] [Related]
9. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
11. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
Font R; Espinas JA; Barnadas A; Izquierdo A; Galceran J; Saladie F; Marcos-Gragera R; Torrent A; Manchon-Walsh P; Borras JM
Breast Cancer Res Treat; 2019 Jun; 175(3):733-740. PubMed ID: 30887164
[TBL] [Abstract][Full Text] [Related]
12. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.
Hadji P; Ziller V; Kyvernitakis J; Bauer M; Haas G; Schmidt N; Kostev K
Breast Cancer Res Treat; 2013 Feb; 138(1):185-91. PubMed ID: 23334803
[TBL] [Abstract][Full Text] [Related]
13. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
15. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
16. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
17. Extended Endocrine Therapy: Is 5 Years Enough?
Bhave MA; Henry NL
Curr Oncol Rep; 2017 Mar; 19(3):16. PubMed ID: 28251491
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.
Wolters R; Schwentner L; Regierer A; Wischnewsky M; Kreienberg R; Wöckel A
Breast Cancer Res Treat; 2012 Feb; 131(3):925-31. PubMed ID: 22080246
[TBL] [Abstract][Full Text] [Related]
19. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
Harborg S; Heide-Jørgensen U; Ahern TP; Ewertz M; Cronin-Fenton D; Borgquist S
Breast Cancer Res Treat; 2020 Aug; 183(1):153-160. PubMed ID: 32572715
[TBL] [Abstract][Full Text] [Related]
20. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
